Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03642054 · ClinicalTrials.gov registry record

Advanced Biomarker Assessment in Pelvic Organ Prolapse

A clinical trial of Pelvic Organ Prolapse, sponsored by Mayo Clinic.

Completed
Registry status
18
Enrollment target
1
Study location

NCT03642054 is a study of Pelvic Organ Prolapse that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants, below the 145-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03642054, a study of Pelvic Organ Prolapse, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
18 participants
Enrollment target
1
Study location

Study Summary

This study will assess advanced biomarkers in patients with and without vaginal prolapse. Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.

Conditions Studied

Study Locations (1)

Arizona

  • Mayo Clinic in Arizona - Phoenix

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-06-29
Est. Completion 2020-05-18

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03642054

The ClinicalTrials.gov registry entry for NCT03642054 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (88% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 0 interventions.

NCT03642054 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT03642054 about?

NCT03642054 is a clinical study titled "Advanced Biomarker Assessment in Pelvic Organ Prolapse". This study will assess advanced biomarkers in patients with and without vaginal prolapse. Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.

What is the current status of trial NCT03642054?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-06-29. Estimated completion is 2020-05-18.

What conditions does trial NCT03642054 study?

This clinical trial studies the following conditions: Pelvic Organ Prolapse.

Who is sponsoring clinical trial NCT03642054?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03642054 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pelvic Organ Prolapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.